ProKidney (NASDAQ:PROK) Shares Gap Up to $2.72

ProKidney Corp. (NASDAQ:PROK - Get Free Report)'s share price gapped up prior to trading on Wednesday . The stock had previously closed at $2.72, but opened at $2.79. ProKidney shares last traded at $2.91, with a volume of 953,997 shares changing hands.

Analyst Ratings Changes

Several research analysts have commented on the stock. Bank of America downgraded shares of ProKidney from a "buy" rating to a "neutral" rating in a report on Tuesday, January 2nd. Morgan Stanley assumed coverage on shares of ProKidney in a report on Thursday, March 7th. They issued an "equal weight" rating and a $3.00 price target for the company.

ProKidney Trading Up 4.4 %

The stock has a market capitalization of $651.33 million, a P/E ratio of -4.98 and a beta of 1.08. The company's fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.80.

ProKidney (NASDAQ:PROK - Get Free Report) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.10. Equities research analysts predict that ProKidney Corp. will post -0.65 earnings per share for the current year.

Insider Transactions at ProKidney

In other news, SVP Darin J. Weber sold 84,103 shares of ProKidney stock in a transaction on Friday, April 12th. The shares were sold at an average price of $1.73, for a total transaction of $145,498.19. Following the completion of the sale, the senior vice president now directly owns 189,670 shares of the company's stock, valued at approximately $328,129.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, SVP Darin J. Weber sold 84,103 shares of ProKidney stock in a transaction on Friday, April 12th. The shares were sold at an average price of $1.73, for a total transaction of $145,498.19. Following the completion of the sale, the senior vice president now directly owns 189,670 shares of the company's stock, valued at approximately $328,129.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Darin J. Weber sold 17,238 shares of the business's stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $2.50, for a total transaction of $43,095.00. Following the completion of the sale, the senior vice president now directly owns 172,432 shares of the company's stock, valued at $431,080. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,641 shares of company stock valued at $189,100. Insiders own 44.99% of the company's stock.

Institutional Trading of ProKidney

Hedge funds have recently added to or reduced their stakes in the business. Jump Financial LLC bought a new stake in ProKidney in the third quarter worth $216,000. SG Americas Securities LLC bought a new stake in ProKidney in the third quarter worth $78,000. HRT Financial LP purchased a new position in shares of ProKidney in the first quarter valued at about $730,000. UBS Group AG increased its position in shares of ProKidney by 97.5% in the first quarter. UBS Group AG now owns 5,209 shares of the company's stock valued at $59,000 after acquiring an additional 2,571 shares during the period. Finally, ExodusPoint Capital Management LP purchased a new position in shares of ProKidney in the first quarter valued at about $151,000. 51.59% of the stock is owned by institutional investors.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.